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Summary Leukocytosis sometimes accompanies malignant neoplasms in the absence of infection. It is
thought that the production of colony-stimulating factor by neoplasms is the most potent cause of tumour-
induced leukocytosis; several mechanisms have been suggested to explain this. We examined 155 human
tumour xenografts established in nude mice, and found that 17 of the xenografts induced remarkable
leukocytosis (>15,000,utl-') in nude rats. We examined granulocyte colony-stimulating factor (G-CSF)
production by the xenografts to study the mechanisms underlying this tumour-induced leukocytosis. Ten of
the 17 xenografted human tumours appeared to express the G-CSF gene. Serum G-CSF increased, to
concentrations of 179-37,218 pg ml-', in host animals transplanted with the ten xenografts expressing the
G-CSF gene transcripts. The biological activity of serum G-CSF also increased, to concentrations of
206-9,074 pg ml-', in the host animals transplanted with the ten xenografts. Immunohistochemical analysis
demonstrated G-CSF production at the cellular level in three of the ten xenografts. These results suggested
that the production of G-CSF is a common event in human tumour xenografts associated with leukocytosis,
but that factors other than G-CSF are also likely to be involved. Leukocytosis induced by neoplasms seems to
be a heterogeneous and complex disorder.
CSF's play an important role in the survival, growth, and
differentiation of hematopoietic progenitor cells both in vitro
and in vivo, the differentiation and proliferation from pro-
genitor cells to mature granulocytes being dependent on its
presence (Metcalf, 1984). CSF's have also been implicated in
the tumour-induced leukocytosis that, rarely, accompanies
various malignant solid tumours in the absence of infection.
This has been suggested in several case reports in which a
clonogenic bioassay was used (Asano et al., 1977; Sato et al.,
1979). However, with bioassay employed in those studies, the
investigators were unable to determine which CSF's were
essential for this leukocytosis. The precise in vivo role of
G-CSF in tumour-induced leukocytosis is still unknown,
although autonomous production of CSF's by human neo-
plasms has been suggested (Lee et al., 1989). In this study, we
examined 155 human tumour xenografts in athymic animals
as an in vivo experimental model of tumour-induced
leukocytosis. We isolated 17 tumour xenografts which
induced leukocytosis in the host animals. To clarify the in
vivo mechanisms underlying tumour-induced leukocytosis, we
examined G-CSF gene expression and G-CSF production in
the human tumour xenografts.
Materials and methods
Human tumour xenografts
One hundred and fifty-five tumour xenograft lines (thyroid
carcinoma, 7; oral cavity carcinoma, 6; lung carcinoma, 26;
gallbladder carcinomas, 6; pancreas carcinoma, 8; biliary
tract carcinoma, 4; adrenal carcinoma, 1; renal carcinoma,
12; uterine cervical carcinoma, 6; mammary gland carcinoma,
7; brain tumour, 7; liver cell carcinoma, 8; gastric carcinoma,
18; eosophageal carcinoma, 2; osteosarcoma, 16; colon car-
cinoma, 6; skin carcinoma, 3; ovarian carcinoma, 3;
choriocarcinoma, 5; and testicular tumour, 4) were estab-
lished and maintained in female BALB/c nude mice (Clea
Japan Inc. Tokyo, Japan). Human primary tumour tissue
was obtained from surgical specimens. Xenografts with 10 to
20 serial passages were used for further analyses.
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We used an in vitro G-CSF-producing cell line, CHU-2
(generously provided by Dr M. Ono, Chugai Pharmaceutical
Co. Ltd., Tokyo, Japan). This cell line was cultured in
RPMI-1640 supplemented with 10% foetal bovine serum in
5% CO2 at 37'C.
White blood cell (WBC) count
The blood volume of nude mice is too small to precisely
examine peripheral blood WBC counts. We usually obtain
0.5 to 1 ml/animal of peripheral blood from nude mice (25 g),
whereas nude rats provide 4- to 8-ml samples were animal
(100 g). In addition, levels of peripheral blood WBC counts
are relatively more stable in nude rats than in nude mice. In
this study, we transplanted human tumour xenografts into
nude rats to estimate peripheral blood WBC counts (F344,
Clea Japan Inc., Tokyo, Japan). Peripheral blood samples
were obtained from the tail veins of nude rats when the
xenografts grew to more than 10 g within 2 months after
transplantation.
Northern blot analysis
We examined the expression of G-CSF transcripts in the
xenografts by Northern blot analysis (Maniatis et al., 1989).
Fifteen ILg of the total RNA samples was run on an agarose
gel and blotted onto a membrane (Gene Screen Plus, New
England Nuclear). A human G-CSF cDNA NcoI/EcoRI
fragment was prepared from a pVR2 plasmid (Nomura et al.,
1986; Nagata et al., 1986). The blots were hybridised with a
G-CSF 32P-labelled cDNA probe under the conditions
recommended by the manufacturer. We evaluated the G-
CSF-specific transcript (1.8 kb) by autoradiography and we
examined housekeeping gene expression by re-hybridisation
of the blots with a P-actin cDNA probe to qualify RNA.
Serum G-CSF levels
We examined sample sera (50p1) withdrawn from the nude
rats within 2 months after the transplantation of the human
tumour xenografts. Serum G-CSF protein levels were
examined by enzyme immunoassay (EIA), using anti-
recombinant human G-CSF polyclonal antibody, as des-
cribed previously (Motojima et al., 1989).
We examined serum G-CSF biological activity by deter-
mining [3H]-thymidine uptake in a G-CSF-dependent murine
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leukaemic cell line, NFS-60 (Shirafuji et al., 1989). NFS-60
cells (2 x 104 cells/well) were cultured in RPMI-1640 with
10% foetal bovine serum and the sample serum for 24h at
37°C under 5% Co2. The [3H]-thymidine incorporation in
cultured cells were determined with a scintillation counter
after 6 h pulsation. The biological activity was shown as the
equivalent value for the recombinant human G-CSF stan-
dard.
Immunohistochemical detection ofG-CSF
An indirect immunostaining method was used, employing
anti-recombinant human G-CSF monoclonal antibody
(Shimamura et al., 1990). Sections were incubated with anti
G-CSF antibody and with a peroxidase-labelled rabbit anti-
mouse immunoglobulin antibody. The visualising reaction
was carried out in 20% 3,3'-diaminobenzidine-4HCl, 0.005%
H202, and 1 M Tris-Cl buffer (pH 7.6).
Results
Peripheral blood WBC count
The peripheral blood WBC count had a mean value of
8,756 gil-1 (s.d. 3,068) in the normal nude rats. The differen-
tial peripheral WBC counts showed 45% neutrophils, 46%
lymphocytes, and 7% monocytes in the normal nude rats.
Seventeen (3 thyroid, 5 lung, 3 oral cavity, 1 gastric, 1 renal,
1 pancreatic, 1 gallbladder, 1 liver cell carcinoma and 1 brain
tumour) of 155 (11%) human tumour xenografts showed
remarkable neutrophilic-dominant leukocytosis, of more than
14,892 gil-', in nude rats (mean + 2 s.d., Table I). Differential
WBC counts revealed that neutrophils (59%-94%) primarily
accounted for the leukocytosis in animals with tumour
xenografts. Patients with primary neoplasms showed various
levels of neutrophilic-dominant leukocytosis (11,400-85,600
gil') without any bacterial infection.
Expression ofG-CSFgene
Northern blot analyses showed a G-CSF transcript (1.8-kb)
in ten of the 17 tumour xenografts (59%) that induced severe
leukocytosis in the host nude rats (Figure 1 and Table II).
These ten tumour xenografts showed heterogeneous levels of
G-CSF gene expression. The G-CSF transcripts showed no
apparent size variation. Northern analysis was also per-
formed in 50 of the 138 tumour xenografts that had no
leukocytosis; no G-CSF transcripts were noted in any of
these 50 tumour xenografts. These results suggested that
autonomous G-CSF production in some tumour xenografts
induced leukocytosis in the host animals.
Serum G-SCF levels
We evaluated G-CSF protein levels in the serum of nude rats
by EIA with anti G-CSF polyclonal antibodies. EIA per-
formed in 30 of the 138 sera from nude rats that had no
leukocytosis, and also in 10 normal nude rats, demonstrated
no detectable levels of G-CSF (< 60 pg ml-') in any of these
sera. The ten tumour xenograft lines expressing the G-CSF
transcripts showed significant increases in serum G-CSF
levels (179-37,218 pg ml-) (Table II). The tumour xenograft
lines that did not appear to express G-CSF transcripts
showed no increase in serum G-CSF levels.
G-CSF biological activity
We confirmed the biological activity of the G-CSF by NFS-
60 cell proliferation assay. The ten human tumour xenografts
that expressed G-CSF transcripts showed significant increases
in G-CSF biological activity (1,259-9,074 pg ml ') (Table
II). The bioassay demonstrated no significant increase in
G-CSF biological activity (<195pgml-') in the nude rats
with human tumour xenografts that did not exhibit G-CSF
gene expression.
Immunohistochemical detection ofG-CSFproduction
We have detected G-CSF production in the tumour xeno-
grafts at the cellular level by immunohistochemical analysis
with anti G-CSF monoclonal antibody. This immunohisto-
chemical method demonstrated G-CSF positive cells in three
out of the ten xenografts that expressed the G-CSF transcript
(Table II), the incidence of G-CSF-positive tumour cells in
these three xeonografts being extremely low (Figure 2). The
tumour xenografts without G-CSF transcripts showed no
G-CSF-positive cells. This immunohistochemical analysis was
also performed in 30 of the 138 tumour xenografts that had
no leukocytosis; no G-CSF-positive cells were found in the
tumour xenografts.
Table I Tumour xenografts associated with leukocytosis in nude rats, and peripheral blood WBC
count in patients
Nude rats
WBC count (/,1)b
(Neutrophil %)d
73,100 (86)
66,000 (94)
49,000 (94)
32,900 (85)
28,200 (75)
25,500 (85)
23,100 (94)
20,000 (88)
20,000 (88)
19,900 (77)
19,500 (73)
18,400 (93)
17,800 (81)
17,800 (85)
17,600 (59)
16,700 (79)
15,700 (60)
Patients
WBC count (Ilt)c
(Neutrophil %)d
51,000 (92)
83,900 (ND)C
27,900 (87)
25,000 (89)
80,000 (89)
85,600 (ND)
27,100 (89)
32,200 (86)
ND
26,000 (84)
11,400 (ND)
ND
ND
12,900 (78)
21,100 (89)
27,000 (92)
ND
aANC, Anaplastic carcinoma; LCC, Large cell carcinoma; SQC, Squamous cell carcinoma; ADC,
adenocarcinoma; SAR, undifferentiated sarcoma; SMC, Small cell carcinoma; RCC, Renal cell
carcinoma; ASC, Adenosquamous carcinoma; HCC, Hepatocellular carcinoma. bPeripheral blood
WBC counts evaluated in nude rats bearing xenografts with weighed 10 g at 1-2 months after
transplantation. cPeripheral blood WBC counts of patients bearing tumours were performed before
surgical removal of the tumours. dDifferential proportion of peripheral blood neutrophilic
leukocytes. eNo data available.
Xenograft
THC-6-JCK
Lu-99
THC-5-JCK
HNC-1-JCK
LJC-1-JCK
OCC-1-JCK
LC-6-JCK
LC-1 1-JCK
GL-4-JCK
THC-2-JCK
LC-18-JCK
RCC-3-JCK
SC-6-JCK
OTUK
PAN-3-JCK
GB-7-JCK
Li-16
Primary
organs
Thyroid
Lung
Thyroid
Oral
Oral
Oral
Lung
Lung
Brain
Thyroid
Lung
Kidney
Stomach
Lung
Pancreas
Gallbladder
Liver
Pathologya
ANC
LCC
ANC
SQC
SQC
SQC
LCC
ADC
SAR
ANC
SMC
RCC
ADC
LCC
ASC
ASC
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Figure 1 Northern blot analyses of G-CSF transcripts in human tumour xenografts associated with severe leukocytosis: Fifteen jtg
of total cellular RNA prepared from the tumour xenograft was fractionated in each lane. a, Tumour xenografts, THC-2-JCK (Lane
1), THC-5-JCK (Lane 2), THC-6-JCK (Lane 3), LJC-1-JCK (Lane 4), OCC-1-JCK (Lane 5), HNC-1-JCK (Lane 6), GB-7-JCK
(Lane 7), Lu-99 (Lane 8), and LC-6-JCK (Lane 9). b, SC-6-JCK (Lane 1), PAN-3-JCK (Lane 2), LC-l l-JCK (Lane 3), LC-18-JCK
(Lane 4), OTUK (Lane 5), RCC-3-JCK (Lane 6), GL-4-JCK (Lane 7), and LI-16 (Lane 8). The band at 1.8 kb indicates G-CSF
transcripts hybridised with the 32P-labelled CDNA. The same blot was rehybridised with the 32P-labelled 13-actin cDNA probe. The
band at 2.2 kb indicates P-actin transcripts. The positive control was RNA prepared from a G-CSF-producing cell line (CHU-2)
cultured in RPMI-1640 with 10% foetal bovine serum.
Table II Production of G-CSF in human tumour xenografts
Tumour G-CSF Serum G-CSF
xenografts transcripts" EIAb Bioassayc
LJC-1-JCK
GB-7-JCK
THC-2-JCK
Lu-99
OTUK
HNC-1-JCK
OCC-1-JCK
THC-6-JCK
THC-5-JCK
LC-6-JCK
LC-18-JCK
LC- 1 -JCK
GL-4-JCK
RCC-3-JCK
PAN-3-JCK
Li-16
SC-6-JCK
37,218
3,092
1,820
998
748
701
596
362
344
179
<60
<60
<60
<60
<60
<60
<60
9,074
5,792
3,175
1,259
366
558
7,304
4,130
206
1,424
<195
<195
<195
<195
<195
<195
<195
Cellular G-CSF
immunohistochemistry'
aG-CSF transcripts detected by Northern blot analysis with 15JLg
total cellular tumour xenograft RNA. bGCSF levels (pgGml') in sera
estimated by EIA. cBiological activity of G-CSF in sera estimated by
NFS-60 cell proliferation assay. The data (pg ml-') are shown as
equivalent values for the recombinant human G-CSF standard.
dG-CSF-positive cells demonstrated by immunohistochemical staining
with anti G-CSF monoclonal antibody.
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a Discussion
In this study, we examined the relationship between
peripheral blood WBC counts and G-CSF gene expression in
tumour xenografts to provide molecular evidence for tumour-
associated leukocytosis. We found severe leukocytosis
(>15,000 phl') in nude rats bearing 17 of 155 human
tumour xenograft lines. Northern blot analyses demonstrated
apparent G-CSF gene expression in ten of these 17 human
tumour xenografts that induced leukocytosis in host nude
rats. These ten tumour xenografts that expressed G-CSF
transcripts secreted biologically-active G-CSF into the serum
of the host nude rats, suggesting that, while the autonomous
production of G-CSF was a major cause of tumour-induced
leukocytosis, G-CSF production did not entirely explain the
leukocytosis seen in the animals. Tumour-induced leuko-
cytosis seems to be a complex disorder caused by various
factors, including G-CSF. Various cytokines, including G-
CSF, granulocytes macrophage-CSF, macrophage-CSF, and
interleukin-3, stimulate the in vitro proliferation of
granulocyte-macrophage progenitor cells (McNice et al.,
4 -*.~~~~~~~ 1989; Nakamura et at., 1991). Monocytes, fibroblasts,
endothelial cells, and bone marrow stromal cells produce
G-CSF under various in vitro conditions (Reinnick et at.,
1987; Fibbe et al., 1989). Cytokines, including interleukin-I
and tumour necrosis factor, modulate G-CSF production by
mesothelial cells (Demetri et at., 1989). These lines of
evidence indicate that the tumour xenografts may have
induced in vivo leukocytosis through G-CSF production by
b their host cells.
.....Using an immunohistochemical method, we detected G-
CSF production in only three out of ten tumour xenografts
that expressed G-CSF transcripts; a low incidence of G-CSF-
positive cells in these three tumour xenografts was also dem-
onstrated by this method. In a previous study (Akatsuka et
.eaturesofporldffretatdqumoselarinat., 1991), we reported that G-CSF products were seen
( x 480) b,ecioofthsmespeimneatedwihntG-SF npredominantly in the perinuclear space and rough surface
antibody. Sections were counterstainedwithmethylgreeendoplasmic recitula without secretory granules in an in vitro
f* ~~~ .... 4 ~~~~~~ cell line (CHU-2). The incidence of tumour cells positive for
..~-- G-CSF in that study was extremely low (approximately 1%) despite the high level of G-CSF gene expression and secre-
4~~p j~~. tion. The low incidence of G-CSF-positive cells in the
*.i.4~~~ ~7i tumour xenografts in this study would appear to be due to
.~~~~~.. ~~~~the rapid secretion of G-CSF without intracellular retention. ~~ hum~~~econfirmed G-CSF production and secretion in the 10
...... ~ ~ ~ ~ ~ ~~uan tumour xenograft lines associated with leukocytosis.
rangement of the G-CSF gene in the tumour xenografts (data Soutshern) canalsisshowhed atneiheomoseplificaion nor rhear
G-CSF gene in the tumour xenografts are not apparent.
It has been shown that G-CSF stimulated the clonogenic
-~~ ~ .~ growth of some nonw-hematopoietic cell lines in vitro (Berdel
et at., 1989; Avalos et at., 1990). The expression of the ~~ ~~~ ~~~ ~G-CSF receptor, as well as the production of G-CSF in
tumour xenografts, requires further analysis.
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Figure 2 Immunohistochemical detection of G-CSF in the Scientific Research from the Ministry of Education, Science and
human tumour xenografts: a, section of human tumour xenograft Culture (M.N., 02770168, 04670188: N.T., 02152110, 03670163,
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colour deposits (arrow) indicate immunoreactive products in the encouragement in this work. We thank Rieko Saegusa for her excel-
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G-CSF was extremely low. (x 480). graphic work.TUMOUR XENOGRAFTS ASSOCIATED WITH LEUKOCYTOSIS 719
References
AKATSUKA, A., SHIMAMURA, K., KATOH, Y., TAKEKOSHI, S.,
NAKAMURA, M., NOMURA, H., HASEGAWA, M., UEYAMA, Y. &
TAMAOKI, N. (1991). Electron microscopic identification of the
intracellular secretion pathway of human G-CSF in a human
tumor cell line: a comparative study with a Chinese hamster
ovary cell line (IAI-7) transfected with human G-CSF cDNA,
Exp. Hematol., 19, 768-772.
ASANO, S., URABE, A., OKABE, T., SATO, N., KONDO, Y., UEYUMA,
Y., CHIBA, S., OHSAWA, N. & KOSAKA, K. (1977). Demonstration
of granulopoietic factor(s) in the plasma of nude mice trans-
planted with a human lung cancer and in the tumor tissue. Blood,
49, 845-852.
AVALOS, B.A., GASSON, J.C., HEDVAT, C., QUAN, S.G., BALDWIN,
G.C., WEISBART, R.H., WILLIAMS, R.E., GOLDE, W.G. & DIPER-
SIO, J.F. (1990). Human granulocyte colony-stimulating factor:
biologic activities and receptor characterization on hematopoietic
cells and small cell lung cancer cell line. Blood, 75, 851-857.
BERDEL, W.E., DANHAUSTER-RIEDL, S., STEILHAUSER, G. & WIN-
TON, E.F. (1989). Various human hematopoietic growth factor
(Interleukin-3, GM-CSF, G-CSF) stimulated clonal growth of
nonhaematopoietic tumor cells. Blood, 73, 80-83.
DEMETRI, G.D., BEATRICE, W.Z., RHEINWALD, J.D. & GRIFFIN,
J.D. (1989). Expression of colony-stimulating factor genes by
normal human mesothelial cells and human malignant
mesothelioma cell lines in vitro. Blod, 74, 940-946.
FIBBE, W.E., DAHA, M.R., HIEMSTRA, P.S., DUINKERKEN, N., LUR-
VINK, E., RALPH, P., ALTROCK, B.W., KAUSHANSKY, K.,
WILLEMZE, R. FALKENBURG, J.H.F. (1989). Interleukin 1 and
poly(rI), poly(rC) induce production of granulocyte CSF, mac-
rophage CSF, and granulocyte-macrophage CSF by human
endothelial cells. Exp. Hematol., 17, 229-234.
LEE, M.Y., KAUSHANSKY, K., JUDKINS, S.A., LOTTSFELDT, J.L.,
WAHEED, A. & SHADDUCK, R.K. (1989). Mechanisms of tumor-
induced neutrophilia: Constitutive production of colony-
stimulating factors and their synergistic actions. Blood, 74,
115-122.
MANIATIS, T., FRITSH, E.F. & SAMBROOK, J. (1989). Molecular
Cloning: A Laboratory Manual. Second edition. Cold Spring
Harbor Laboratory Press: New York.
McNICE, I., ANDREWS, R. & STEWART, M. (1989). Action of
interleukin-3, G-CSF, and GM-CSF on highly enriched human
hematopoietic progenitor cells: Synergistic interaction of GM-
CSF plus G-CSF, Blood, 74, 110-114.
METCALF, D. (1984). The Hematopoietic Colony Stimulating Fac-
tors. Elsevier Science Publishers: Amsterdam-New York.
MOTOJIMA, H., KOBAYASHI, T., SHIMANE, M., KAMACHI, S. &
FUKUSIMA, M. (1989). Quantitative enzyme immunoassay for
human granulocyte colony-stimulating factor (G-CSF). J.
Immunol. Meth., 118, 187-192.
NAKAMURA, K., TAKAHASHI, T., TSUYUOKA, R., UEDA, Y.,
SUZUKI, A., OKUNO, Y., IHARA, Y., SEKO, S., OKADA, T.,
KUMAGAI, N., OYAIZU, T. & NISHIMURA, T. (1991).
Identification of colony-stimulating factor activity in patients
with malignant tumors associated with excessive leukocytosis.
Jpn. J. Clin. Oncol., 21, 395-399.
NAGATA, S., TSUCHIYA, M., ASANO, S., KAZIRO, Y., YAMAZAKI,
T., YAMAMOTO, O., HIRATA, Y., KUBOTA, N., OHEDA, M.,
NOMURA, H. & ONO, M. (1986). Molecular cloning and expres-
sion of cDNA for human granulocyte colony-stimulating factor.
Nature, 319, 415-417.
NOMURA, H., IMAZEKI, I., OHEDA, M., KUBOTA, N., TAMURA, M.,
ONO, M., UEYAMA, Y. & ASANO, S. (1986). Purification and
characterization of human granulocyte colony-stimulting factor
(G-CSF). EMBO J., 5, 871-876.
RENNICK, D., YANG, G., GEMMELL, L. & LEE, F. (1987). Control of
hemopoiesis by a bone marrow stromal cell clone: Lipopolysac-
charide and interleukin 1-inducible production of colony-
stimulating factor. Blood, 69, 682-691.
SATO, N., ASANO, S., UEYAMA, Y., MORI, M., OKABE, T., KONDO,
Y., OHSAWA, N. & KOSAKA, K. (1979). Granulocytosis and
colony-stimulating activity (CSA) and produced by a human
squamous cell carcinoma. Cancer, 43, 605-610.
SHIMAMURA, K., FUJIMOTO, J., HATA, J., AKATSUKA, A.,
UEYAMA, Y., WATANABE, T. & TAMAOKI, N. (1990). Establish-
ment of specific monoclonal antibodies against recombinant
human granulocyte colony-stimulating factor (hG-CSF) and their
application for immunoperoxidase staining of paraffin-embedded
sections. J. Histochem. Cytochem., 38, 283-286.
SHIRAFUJI, N., ASANO, S., MATSUDA, S., WATARI, K., TAKAKU, F.
& NAGATA, S. (1989). A new bioassay for human granulocyte
colony stimulating factor (G-CSF) using murine myeloblastic
NFS-60 cells as targets and estimation of its level in sera from
normal healthy persons and patients with infections and
hematological disorder. Exp. Hematol., 17, 116-119.